Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyWellfleet PRP Coverage Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentWellfleetPolicy GL-019

    Platelet-Rich Plasma Injections

    Customize your policy alerts

    Sign up for wellfleet Policy GL-019 alerts

    Get alerted when Policy GL-019 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Describes how Wellfleet evaluates and reviews platelet-rich plasma utilization for specified orthopedic and musculoskeletal conditions for providers submitting claims for covered Wellfleet plan members.

    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateSep 1, 2022
    Next Review DateSep 1, 2023
    Key ActionSubmit any PRP utilization not listed in the guideline's evaluation grid for physician review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    11Specific PRP utilization areas evaluated
    3Possible utilization review outcomes
    Physician reviewReview required for unlisted utilization
    Investigational/ExperimentalInvestigational/experimental designation
    RN reviewApproval pathway for selected indications

    PRP Utilization Review Criteria

    Investigational or Experimental Indications

    The following listed PRP uses are designated investigational/experimental, either categorically or for the specified use or condition.

    ALL of the following

    • Achilles tendinopathy — investigational/experimental.
    • Achilles rupture — investigational/experimental; surgical treatment is required for Achilles tendon rupture.
    • Anterior cruciate ligament injury or reconstruction when used intra-operatively for surgical ACL reconstruction — investigational/experimental.
    • Knee injections for osteoarthritis — investigational/experimental.
    Policy Summary
    PayerWellfleet
    PolicyPlatelet-Rich Plasma Injections
    Policy CodePolicy GL-019
    Change TypeNo material change
    Effective DateSep 1, 2022
    Next Review DateSep 1, 2023
    Key ActionSubmit any PRP utilization not listed in the guideline's evaluation grid for physician review.
    SourceLink
    On This Page
    PRP Utilization Review CriteriaProvider Submission and Review RequirementsClinical BackgroundKey Terms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Meniscal tears — investigational/experimental.
  1. Plantar fasciitis — investigational/experimental as indicated in the utilization grid; the grid also identifies this indication for approval after RN review.
  2. Rotator cuff injuries — investigational/experimental for tears other than tendinopathy and partial tears; the grid also identifies rotator cuff use for approval after RN review.
  3. Ankle injections for osteoarthritis — investigational/experimental as indicated in the utilization grid; the grid also identifies this indication for approval after RN review.
  4. Approval After RN Review

    The following listed uses may be approved after review by a registered nurse (RN), subject to the indication-specific conditions in the utilization grid.

    ALL of the following

    • Ankle injections for osteoarthritis — may be approved after RN review.
    • Anterior cruciate ligament injury or reconstruction without surgery — may be approved after RN review.
    • Surgical ACL reconstruction donor site, patellar tendon — may be approved after RN review when the request is for surgical application.
    • Lateral epicondylitis — may be approved after RN review when the request includes highly cellular leukocyte-rich PRP (LR-PRP).
    • Plantar fasciitis — may be approved after RN review as indicated in the utilization grid.
    • Rotator cuff injuries — may be approved after RN review for tendinopathy and partial tears.
    • Ulnar collateral ligament injury — may be approved after RN review.

    Refer for Physician Review

    The following listed uses require referral for physician review.

    ALL of the following

    • Lateral epicondylitis — refer for physician review when the request is without highly cellular leukocyte-rich PRP (LR-PRP).
    • Muscle injury — refer for physician review.
    • Other or unspecified PRP utilization identified in the grid — refer for physician review.

    Evidence Supporting Determinations

    The supporting information in the utilization grid includes the following evidence summaries.

    ALL of the following

    • Achilles tendinopathy: randomized controlled trials (RCTs) failed to show superiority of PRP compared with placebo or physiotherapy.
    • Achilles rupture: surgical treatment is required.
    • Ankle osteoarthritis: a 2021 randomized clinical trial found that intra-articular PRP did not significantly improve symptoms or function compared with placebo over 26 weeks; two studies reported positive injection results.
    • ACL injury or reconstruction: two studies showed positive results for injection without surgery. Systematic reviews found no beneficial effects when PRP was used intra-operatively for clinical outcome, bone-graft integration, or prevention of bony tunnel enlargement.
    • Surgical ACL reconstruction patellar tendon donor site: recent studies found improved healing and pain with surgical PRP application to the harvest site.
    • Knee osteoarthritis: the RESTORE randomized clinical trial found no significant difference in symptoms or joint structure at 12 months between intra-articular PRP and saline placebo.
    • Lateral epicondylitis: studies using varied controls have produced inconsistent results. Some meta-analyses found reduced pain, while others were equivocal or negative; evidence was more favorable for highly cellular LR-PRP, but studies were limited and heterogeneous.
    • Meniscal tears: few, small, and contradictory studies are available, so no definite conclusions can be drawn.
    • Muscle injury: non-randomized studies suggested improved tissue repair or faster functional recovery, while RCTs showed controversial results; one small RCT reported improved recovery, return to sport, and pain management, whereas subsequent studies showed no benefit.
    • Plantar fasciitis: studies are conflicting and generally low quality, showing marginal benefit, no short- or intermediate-term pain benefit, and only limited evidence for long-term pain relief.
    • Rotator cuff injuries: meta-analysis of RCTs found PRP was not worse than corticosteroid injection for pain relief and functional recovery, with possible reductions in subsequent injection or surgery and improved medium- to long-term outcomes; three small athlete studies reported improvement for the specified tears.
    • Ulnar collateral ligament injury: three small studies in athletes showed improved outcomes.

    The guideline describes how Wellfleet considers and reviews platelet-rich plasma (PRP) injections. The utilization grid contains eleven specific PRP indications and identifies whether each is approved after RN review, referred for physician review, or investigational/experimental.

    Provider Submission and Review Requirements

    Prior Authorization

    Review Required for Unlisted Utilization

    Use the PRP utilization grid to determine the applicable review pathway before submitting a claim. Listed services may be approved after RN review when the grid indicates approval; services marked for referral, and any utilization not listed in the grid, require physician review.

    • Confirm the diagnosis or procedure matches one of the guideline’s eleven listed PRP utilization areas.
    • Follow the grid designation: RN review for applicable approvals, physician review for referred services, and physician review for all unlisted utilization.
    Documentation Required

    Submit Accurate Claims and Supporting Records

    Providers are responsible for submitting accurate claims for PRP services. Wellfleet may request supporting documentation, including provider records, for claims submitted.

    • Submit claims with accurate procedure, diagnosis, and utilization information.
    • Provide supporting documentation and provider records promptly when requested by Wellfleet.
    Denial Risk

    Investigational or Unlisted PRP Use

    PRP utilization designated investigational/experimental in the guideline is noncovered. PRP use that is not listed in the utilization grid is also subject to physician review and may be determined noncovered based on that review.

    • Do not assume coverage for PRP services marked investigational/experimental, including applicable listed indications.
    • Obtain physician review for any PRP diagnosis or procedure not included in the grid.
    • Include sufficient clinical documentation to support physician review of investigational or unlisted PRP use.

    Clinical Background

    Platelet-rich plasma (PRP) injections use autologous, platelet-containing blood products with the intent of supporting tissue healing or reducing pain. In this orthopedic and musculoskeletal guideline, Wellfleet evaluates PRP use across tendon, ligament, muscle, meniscal, joint, and rotator cuff conditions. The evidence is condition-specific and ranges from approval after RN review to physician referral or investigational/experimental status.

    Key Terms

    Platelet-rich plasma (PRP)
    TermPlatelet-rich plasma (PRP)
    DefinitionA blood-derived product containing concentrated platelets.
    UseInjected or applied for orthopedic and musculoskeletal conditions.
    Leukocyte-rich PRP (LR-PRP)
    TermLeukocyte-rich PRP (LR-PRP)
    DefinitionA highly cellular form of platelet-rich plasma containing a high concentration of leukocytes.
    Identifying characteristicThe guideline identifies LR-PRP as highly cellular leukocyte-rich PRP.